Skip to main content

Biogen Alzheimer’s Approval Could Signal FDA’s Flexibility

Last week, the Food & Drug Administration (FDA) approved Biogen’s Aducanumab, a potentially revolutionary Alzheimer’s treatment. While the approval represents one of the first landmarks in the quest to improve outcomes for Alzheimer’s patients, the news wasn’t without...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.